.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Express Scripts
Novartis
Teva
Julphar
Fuji
Cerilliant
Dow
Citi
Covington

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Compositions including triciribine and trastuzumab and methods of use thereof
Abstract: This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
Inventor(s): Cheng; Jin Q. (Tampa, FL), Sebti; Said M. (Tampa, FL)
Assignee: University of South Florida (Tampa, FL)
Application Number:14/881,777
Patent Claims:1. A method of treating a tumor or cancer that overexpressed AKT in a mammal comprising administering to the mammal an effective amount of a composition comprising: (i) a compound of formula I: ##STR00011## wherein each R.sub.2', R.sub.3' and R.sub.5' are independently hydrogen, optionally substituted phosphate or phosphonate; acyl; alkyl; amide, sulfonate ester including alkyl or arylalkyl; sulfonyl, methanesulfonyl, benzylsulfonyl; optionally substituted arylsulfonyl; a lipid, a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound wherein R.sub.2', R.sub.3' and R.sub.5' is independently H or mono-, di- or tri-phosphate; wherein R.sup.x and R.sup.y are independently hydrogen, optionally substituted phosphate; acyl; amide, alkyl; aromatic, polyoxyalkylene such as polyethyleneglycol, optionally substituted arylsulfonyl; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group; R.sub.1 and R.sub.2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl; and (ii) trastuzumab or a salt thereof; wherein the compound of formula I is administered to said mammal in an amount of at least 10 mg/m.sup.2.

2. The method of claim 1, wherein a compound of formula I and trastuzumab or a salt thereof are administered simultaneously.

3. The method of claim 1, wherein a compound of formula I is administered followed by the administration of trastuzumab or a salt thereof.

4. The method of claim 1, wherein the trastuzumab or a salt thereof is administered followed by the administration of a compound of formula I.

5. The method of claim 1, wherein the compound of formula I is administered one time per week for three weeks followed by a one-week period wherein the compound is not administered.

6. The method of claim 1, wherein the trastuzumab or a salt thereof is administered one time per week for three weeks followed by a one-week period wherein the compound is not administered.

7. The method of claim 6, wherein the dosing schedule is repeated at least twice.

8. The method of claim 6, wherein the dosing schedule is repeated at least 4 times.

9. The method of claim 1, wherein the tumor treated is breast, pancreatic, ovarian and colorectal tumors.

10. The method of claim 1, wherein at least 100 mg of trastuzumab or a salt thereof is administered.

11. The method of claim 1, wherein at least 200 mg of trastuzumab or a salt thereof is administered.

12. The method of claim 1, wherein at least 400 mg of trastuzumab or a salt thereof is administered.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe University of South Florida (Tampa, FL) Cheng; Jin Q. (Tampa, FL), Sebti; Said M. (Tampa, FL) ► SubscribeRXOrphansearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Australia2005228410Oct 13, 2005
Canada2561513Oct 13, 2005
Canada2724246Nov 19, 2009
China1984663Jun 20, 2007
Denmark2574341Jun 26, 2017
European Patent Office1737472Aug 13, 2014
European Patent Office1737472Jan 03, 2007
European Patent Office1737472Sep 01, 2010
European Patent Office2300055Mar 30, 2011
European Patent Office2574341Apr 03, 2013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Chubb
Moodys
Mallinckrodt
Merck
Dow
Daiichi Sankyo
Novartis
Cantor Fitzgerald
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot